Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes

Diabetes Care ◽  
2008 ◽  
Vol 31 (Supplement 2) ◽  
pp. S140-S145 ◽  
Author(s):  
J. C. Pickup ◽  
E. Renard
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Pump ◽  
Insulin Pump Therapy ◽  
Insulin Analogs ◽  
Pump Therapy ◽  
Acting Insulin ◽  
Long Acting

scholarly journals CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. e045650
Author(s):  
Sidse Kjærhus Nørgaard ◽  
Elisabeth Reinhardt Mathiesen ◽  
Kirsten Nørgaard ◽  
Tine Dalsgaard Clausen ◽  
Peter Damm ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Pump ◽  
Controlled Trial ◽  
Insulin Pump Therapy ◽  
Pump Therapy ◽  
Acting Insulin ◽  
Pregnancy And Lactation ◽  
Randomised Controlled

IntroductionFaster-acting insulin aspart (Fiasp) is approved for use in pregnancy and lactation, but no clinical study has evaluated its effects during this life stage in women with pre-existing diabetes. The aim of the CopenFast trial is to evaluate the effect of Fiasp compared with insulin aspart (NovoRapid) on maternal glycaemic control during pregnancy, delivery and lactation and on fetal growth and infant health.Methods and analysisAn open-label randomised controlled trial of pregnant women with type 1 or type 2 diabetes including women on multiple daily injection (MDI) therapy or insulin pump therapy. During a 2-year inclusion period, approximately 220 women will be randomised 1:1 to Fiasp or NovoRapid in early pregnancy and followed until 3 months after delivery. At 9, 21 and 33 gestational weeks and during planned induction of labour or caesarean section, women are offered blinded continuous glucose monitoring (CGM) for 7 days. Randomisation will stratify for type of diabetes and insulin treatment modality (MDI or insulin pump therapy, respectively). Health status of the infants will be followed until 3 months of age. The primary outcome is birth weight SD score adjusted for gestational age and gender. Secondary outcomes include maternal glycaemic control including glycated haemoglobin, preprandial and postprandial self-monitored plasma glucose levels, episodes of mild and severe hypoglycaemia, maternal gestational weight gain and weight retention, CGM time spent in, above and below target ranges as well as pregnancy outcomes including pre-eclampsia, preterm delivery, perinatal mortality and neonatal morbidity. Data analysis will be performed according to the intention-to-treat principle.Ethics and disseminationThe trial has been approved by the Regional Ethics Committee (H-19029966) on 7 August 2019. Results will be sought disseminated in peer-reviewed journals and at scientific meetings.Trial registration numberNCT03770767

Retrospective Analysis and Patient Satisfaction Assessment of Insulin Pump Therapy in Patients with Type 2 Diabetes

2011 ◽  
Vol 104 (1) ◽  
pp. 24-28 ◽  
Author(s):  
Chad K. Gentry ◽  
L. Brian Cross ◽  
Benjamin N. Gross ◽  
M. Shawn McFarland ◽  
William H. Bestermann
Keyword(s):  
Type 2 Diabetes ◽  
Patient Satisfaction ◽  
Retrospective Analysis ◽  
Insulin Pump ◽  
Insulin Pump Therapy ◽  
Pump Therapy

scholarly journals The role of insulin pump therapy for type 2 diabetes mellitus

2016 ◽  
Vol 33 (1) ◽  
pp. e2822 ◽  
Author(s):  
Zohar Landau ◽  
Itamar Raz ◽  
Julio Wainstein ◽  
Yosefa Bar-Dayan ◽  
Avivit Cahn
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Pump ◽  
Insulin Pump Therapy ◽  
Pump Therapy
Sign in / Sign up

Export Citation Format

Share Document